You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Alzheimer's disease (AD) is the most common type of neurodegenerative disorder in the ageing population, with dementia as a common consequence. AD is defined pathologically by the appearance of extracellular senile plaques and intracellular neurofibrillary tangles, as described by Alois Alzheimer about a century ago. The causes for AD include genetic predisposition in a small population, ageing and environmental stresses in majority cases. The underlying pathogenic cascades, increases in expression of amyloid precursor protein and accumulation of Aß and reactive oxidant activity and inflammation, have the features of both adaptive, at least initially, and harmful when becoming excessive. De...
With people aged 65 years and older currently making up the fastest growing age group throughout the world, the demographic revolution of an aging society will inevitably lead to increased pressure to develop a rationalistic and age-tailored process of diagnosis and treatment among the elderly. As aging people often suffer from several chronic diseases and are being treated with multiple medications concurrently, unwanted drug interactions occur more frequently. Whereas recent approaches have recommended to remove particular drugs from the medication regimen to avoid adverse effects, Drug Therapy for the Elderly underlines both indispensable and dispensable elements of drug treatment in order to provide an overall assessment of drugs suitable for the aged. In view of the multimorbidity and polypharmacy situations experienced by elderly patients, this book takes into account the special needs and requirements shown by this group, thus serving as a timely reference for physicians who treat the elderly.
Abstract: Older patients with depression or Alzheimer's disease (AD) at the stage of early dementia or mild cognitive impairment may present with objective cognitive impairment, although the pathology and thus therapy and prognosis differ substantially. In this study, we assessed the potential of an automated algorithm to categorize a test set of 65 T1-weighted structural magnetic resonance images (MRI). A convenience sample of elderly individuals fulfilling clinical criteria of either AD (n = 28) or moderate and severe depression (n = 37) was recruited from different settings to assess the potential of the pattern recognition method to assist in the differential diagnosis of AD versus depre...
This book represents the third in a series of International Conferences related to Alzheimer's (AD) and Parkinson's (PD) diseases. The first one took place in Eilat, Israel, in 1985; and the second one in Kyoto, Japan, in 1989. This book contains the full text of oral and poster presentations from the Third International Conference on Alzheimer's and Parkinson's Diseases: Recent Developments, held in Chicago, Illinois, U.S.A. on November 1-6, 1993. The Chicago Conference was attended by 270 participants. The Scientific Program was divided into nine oral sessions, a keynote presentation, and a poster session. The conference culminated in a Round Table Discussion involving all of the participants in the conference. The four and one-half day meeting served as an excellent medium for surveying the current status of clinical and preclinical developments in AD and PD. There were 59 oral presentations and 93 posters. This book incorporates a majority of both.
This book offers an interdisciplinary reflection on the scientific and ethical issues of the notion of proof in medicine. The book poses the following questions: why does an argument convince? How does one make a rational decision in the face of contradictory data? Why and how can we prioritize levels of evidence? What is the value of physicians' professional experience in the production of evidence? By asking these questions, this book highlights the debates surrounding the notions of robustness, relevance and statistical significance regarding different conceptions of the reliability of biomedical knowledge. It is intended for both biomedical scientists (clinicians, epidemiologists, biostatisticians, etc.) and researchers in the social sciences and humanities who are interested in the social organization of clinical trials and in decision-making in a context of uncertainty. It also provides a better understanding of social issues in specific contexts, such as gynecological care, prevention policies, significance tests, and the management of the COVID-19 pandemic.